Identified potential biomarkers may predict primary nonresponse to infliximab in patients with ulcerative colitis

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Haberman Y, Karns R, Dexheimer PJ, et al. Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response. Nat Commun. 2019;10(1):38.
   PubMedGoogle Scholar
• Chen X, Jiang L, Han W, et al. Artificial neural network analysis-based immune-related signatures of primary non-response to infliximab in patients with ulcerative colitis. Front Immunol. 2021;12:742080.
   PubMed Web of Science ®Google Scholar
• Alsoud D, Verstockt B, Fiocchi C, et al. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6(7):589–595.
   PubMed Web of Science ®Google Scholar
• Zeissig S, Rosati E, Dowds CM, et al. Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease. Gut. 2019;68(1):25–39.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Colombel JF, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol. 2019;114(6):874–883.
   PubMed Web of Science ®Google Scholar
• Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017;357:j2505.
   PubMed Web of Science ®Google Scholar
• Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(2):162–175.
   PubMed Web of Science ®Google Scholar
• Gilmore R, Hilley P, Srinivasan A, et al. Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis. J Crohns Colitis. 2022;16(1):166–168.
   PubMed Web of Science ®Google Scholar
• Lamberg T, Sipponen T, Valtanen S, et al. Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases. Autoimmunity. 2022;55(5):275–284.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang J, Wu D, et al. Associations between TNFSF15 polymorphisms and susceptibility to ulcerative colitis and Crohn’s disease: a Meta-analysis. Autoimmunity. 2014;47(8):512–518.
   PubMed Web of Science ®Google Scholar
• Karmi N, Bangma A, Spekhorst LM, et al. Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease. PLoS One. 2021;16(9):e0256860.
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25(1):25–29.
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.
   PubMed Web of Science ®Google Scholar
• Luan H, Zhang C, Zhang T, et al. Identification of key prognostic biomarker and its correlation with immune infiltrates in pancreatic ductal adenocarcinoma. Dis Markers. 2020;2020:8825997.
   PubMed Web of Science ®Google Scholar
• Yang X, Li Y, Lv R, et al. Study on the multitarget mechanism and key active ingredients of herba siegesbeckiae and volatile oil against rheumatoid arthritis based on network pharmacology. Evid Based Complement Alternat Med. 2019;2019:8957245.
   PubMed Web of Science ®Google Scholar
• LeBlanc K, Mosli MH, Parker CE, et al. The impact of biological interventions for ulcerative colitis on health-related quality of life. Cochrane Database Syst Rev. 2015;2015(9):CD008655.
   PubMed Web of Science ®Google Scholar
• Paschos P, Katsoula A, Salanti G, et al. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018;48(11–12):1174–1185.
   PubMed Web of Science ®Google Scholar
• Izadi Z, Brenner EJ, Mahil SK, et al. Association between tumor necrosis factor inhibitors and the risk of hospitalization or death among patients with immune-mediated inflammatory disease and COVID-19. JAMA Netw Open. 2021;4(10):e2129639.
   PubMed Web of Science ®Google Scholar
• Mei WQ, Hu HZ, Liu Y, et al. Infliximab is superior to other biological agents for treatment of active ulcerative colitis: a meta-analysis. World J Gastroenterol. 2015;21(19):6044–6051.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Rivals-Lerebours O, Billiet T, et al. Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab. J Cronhs Colitis. 2016;10(9):1015–1023.
   PubMed Web of Science ®Google Scholar
• Dovrolis N, Michalopoulos G, Theodoropoulos GE, et al. The interplay between mucosal microbiota composition and host gene-expression is linked with infliximab response in inflammatory bowel diseases. Microorganisms. 2020;8(3):438.
   Web of Science ®Google Scholar
• Zimmer DB, Eubanks JO, Ramakrishnan D, et al. Evolution of the S100 family of calcium sensor proteins. Cell Calcium. 2013;53(3):170–179.
   PubMed Web of Science ®Google Scholar
• Hadley T, Gillespie S, Espinoza H, et al. Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. Autoimmunity. 2020;53(5):253–260.
   PubMed Web of Science ®Google Scholar
• Dai J, Kumbhare A, Youssef D, et al. Intracellular S100A9 promotes myeloid-derived suppressor cells during late sepsis. Front Immunol. 2017;8:1565.
   PubMed Web of Science ®Google Scholar
• Song R, Struhl K. S100A8/S100A9 cytokine acts as a transcriptional coactivator during breast cellular transformation. Sci Adv. 2021;7(1):eabe5357.
   PubMed Web of Science ®Google Scholar
• Brynjolfsson SF, Magnusson MK, Kong PL, et al. An antibody against triggering receptor expressed on myeloid cells 1 (TREM-1) dampens proinflammatory cytokine secretion by lamina propria cells from patients with IBD. Inflamm Bowel Dis. 2016;22(8):1803–1811.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Verstockt S, Dehairs J, et al. Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. EBioMedicine. 2019;40:733–742.
   PubMed Web of Science ®Google Scholar
• Kvedaraite E. Neutrophil-T cell crosstalk in inflammatory bowel disease. Immunology. 2021;164(4):657–664.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Hosomi S, Yamagami H, et al. Neutrophil-to-lymphocyte ratio for predicting loss of response to infliximab in ulcerative colitis. PLoS One. 2017;12(1):e0169845.
   PubMed Web of Science ®Google Scholar
• Bertani L, Rossari F, Barberio B, et al. Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio. Inflamm Bowel Dis. 2020;26(10):1579–1587.
   PubMed Web of Science ®Google Scholar
• Simard JC, Noël C, Tessier PA, et al. Human S100A9 potentiates IL-8 production in response to GM-CSF or fMLP via activation of a different set of transcription factors in neutrophils. FEBS Lett. 2014;588(13):2141–2146.
   PubMed Web of Science ®Google Scholar
• Carrasco K, Boufenzer A, Jolly L, et al. TREM-1 multimerization is essential for its activation on monocytes and neutrophils. Cell Mol Immunol. 2019;16(5):460–472.
   PubMed Web of Science ®Google Scholar